CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RPS25 (ImmuneEditome ID:6230)

1. Gene summary of enriched editing regions for RPS25

check button Gene summary
Gene informationGene symbol

RPS25

Gene ID

6230

GeneSynonymsS25|eS25
GeneCytomap

11q23.3

GeneTypeprotein-coding
GeneDescription40S ribosomal protein S25|small ribosomal subunit protein eS25
GeneModificationdate20230409
UniprotIDP62851;E9PQK3;E9PK60
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr11:119016073-119016943:-ENST00000527853.1ENSG00000118181.9RPS25ncRNA_intronicAluSz,AluJb,AluSx,FLAM_Cchr11:119016073-119016943:-.alignment


Top

2. Tumor-specific enriched editing regions for RPS25


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr11:119016073-119016943:-CESCEER2.6302e-021.2959e-022.7809e+03image

Top

3. Enriched editing regions and immune related genes for RPS25


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for RPS25


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for RPS25


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000118181.9,RPS25DLBCEAGNeutrophils1.7389e-030.5741image
chr11:119016073-119016943:-ESCAEERT_cells_CD4_naive1.5054e-020.2556image
ENSG00000118181.9,RPS25ESCAEAGT_cells_CD4_naive1.5054e-020.2556image
chr11:119016073-119016943:-GBMEERMacrophages_M04.8223e-03-0.4477image
ENSG00000118181.9,RPS25GBMEAGMacrophages_M04.8223e-03-0.4477image
chr11:119016073-119016943:-KIRCEERMonocytes9.3578e-030.2771image
ENSG00000118181.9,RPS25KIRCEAGMonocytes9.3578e-030.2771image
ENSG00000118181.9,RPS25LAMLEAGMacrophages_M14.3908e-020.3585image
chr11:119016073-119016943:-LGGEERMast_cells_activated1.9891e-02-0.2522image
ENSG00000118181.9,RPS25LGGEAGMast_cells_activated1.9891e-02-0.2522image
chr11:119016073-119016943:-LIHCEERNeutrophils3.2114e-030.4841image
ENSG00000118181.9,RPS25LIHCEAGNeutrophils3.2114e-030.4841image
chr11:119016073-119016943:-LUADEERPlasma_cells4.5833e-02-0.1462image
ENSG00000118181.9,RPS25LUADEAGPlasma_cells4.5833e-02-0.1462image
chr11:119016073-119016943:-OVEERDendritic_cells_resting3.2655e-020.1584image
ENSG00000118181.9,RPS25OVEAGDendritic_cells_resting2.9748e-020.1612image
chr11:119016073-119016943:-PCPGEERT_cells_regulatory_(Tregs)3.2842e-020.4196image
ENSG00000118181.9,RPS25PCPGEAGT_cells_regulatory_(Tregs)3.2842e-020.4196image
chr11:119016073-119016943:-PRADEERDendritic_cells_activated4.1500e-020.1604image
ENSG00000118181.9,RPS25PRADEAGDendritic_cells_activated4.1500e-020.1604image
chr11:119016073-119016943:-READEERNeutrophils9.6275e-040.6089image
ENSG00000118181.9,RPS25READEAGNeutrophils9.6275e-040.6089image
chr11:119016073-119016943:-SARCEERT_cells_regulatory_(Tregs)4.1226e-030.4729image
ENSG00000118181.9,RPS25SARCEAGT_cells_regulatory_(Tregs)4.1226e-030.4729image
chr11:119016073-119016943:-SKCMEERMast_cells_resting1.7483e-020.2962image
ENSG00000118181.9,RPS25SKCMEAGMast_cells_resting1.7483e-020.2962image
chr11:119016073-119016943:-TGCTEERPlasma_cells1.8114e-020.2838image
ENSG00000118181.9,RPS25TGCTEAGPlasma_cells1.8114e-020.2838image
chr11:119016073-119016943:-THCAEERMonocytes2.0703e-020.2288image
ENSG00000118181.9,RPS25THCAEAGMonocytes2.0703e-020.2288image
ENSG00000118181.9,RPS25THYMEAGT_cells_CD4_memory_resting1.3707e-02-0.3306image
chr11:119016073-119016943:-UCECEERMast_cells_activated4.9324e-020.2102image
ENSG00000118181.9,RPS25UCECEAGMast_cells_activated4.7488e-020.2107image
chr11:119016073-119016943:-UCSEERT_cells_gamma_delta3.9306e-020.3551image
ENSG00000118181.9,RPS25UCSEAGT_cells_gamma_delta3.9306e-020.3551image


Top

6. Enriched editing regions and immune gene sets for RPS25


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000118181.9,RPS25CESCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.2066e-020.2237image
ENSG00000118181.9,RPS25DLBCGSVA_HALLMARK_COMPLEMENTEAG7.7425e-030.5012image
ENSG00000118181.9,RPS25ESCAGSVA_HALLMARK_MYOGENESISEAG3.2013e-030.3074image
chr11:119016073-119016943:-ESCAGSVA_HALLMARK_MYOGENESISEER3.2013e-030.3074image
chr11:119016073-119016943:-GBMGSVA_HALLMARK_HYPOXIAEER2.9113e-02-0.3542image
ENSG00000118181.9,RPS25GBMGSVA_HALLMARK_HYPOXIAEAG2.9113e-02-0.3542image
chr11:119016073-119016943:-KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.4278e-030.2957image
ENSG00000118181.9,RPS25KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG5.4278e-030.2957image
chr11:119016073-119016943:-KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER3.7959e-02-0.3104image
ENSG00000118181.9,RPS25KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.7959e-02-0.3104image
ENSG00000118181.9,RPS25LAMLGSVA_HALLMARK_MYC_TARGETS_V2EAG2.5965e-02-0.3933image
chr11:119016073-119016943:-LGGGSVA_HALLMARK_DNA_REPAIREER2.9833e-030.3184image
ENSG00000118181.9,RPS25LGGGSVA_HALLMARK_DNA_REPAIREAG2.9833e-030.3184image
ENSG00000118181.9,RPS25LIHCGSVA_HALLMARK_COMPLEMENTEAG2.6339e-020.3752image
chr11:119016073-119016943:-LIHCGSVA_HALLMARK_COMPLEMENTEER2.6339e-020.3752image
chr11:119016073-119016943:-LUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.8803e-020.1599image
ENSG00000118181.9,RPS25LUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.8803e-020.1599image
ENSG00000118181.9,RPS25LUSCGSVA_HALLMARK_UV_RESPONSE_UPEAG2.8629e-020.1486image
chr11:119016073-119016943:-LUSCGSVA_HALLMARK_UV_RESPONSE_UPEER2.8629e-020.1486image
ENSG00000118181.9,RPS25OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG5.2747e-030.2060image
chr11:119016073-119016943:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.8073e-030.2135image
ENSG00000118181.9,RPS25PAADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG8.7712e-030.3599image
chr11:119016073-119016943:-PAADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER8.7712e-030.3599image
ENSG00000118181.9,RPS25PRADGSVA_HALLMARK_APICAL_SURFACEEAG4.9216e-020.1548image
chr11:119016073-119016943:-PRADGSVA_HALLMARK_APICAL_SURFACEEER4.9216e-020.1548image
ENSG00000118181.9,RPS25READGSVA_HALLMARK_APICAL_JUNCTIONEAG8.1806e-040.6155image
chr11:119016073-119016943:-READGSVA_HALLMARK_APICAL_JUNCTIONEER8.1806e-040.6155image
chr11:119016073-119016943:-STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER8.0981e-030.2547image
ENSG00000118181.9,RPS25STADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.0981e-030.2547image
ENSG00000118181.9,RPS25THCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.1424e-02-0.2132image
chr11:119016073-119016943:-THCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.1424e-02-0.2132image
ENSG00000118181.9,RPS25THYMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.2868e-02-0.3334image
chr11:119016073-119016943:-UCSGSVA_HALLMARK_PROTEIN_SECRETIONEER4.3392e-02-0.3485image
ENSG00000118181.9,RPS25UCSGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.3392e-02-0.3485image


Top

7. Enriched editing regions and drugs for RPS25


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000118181.9,RPS25BLCAMetforminEAG3.2350e-020.1619image
chr11:119016073-119016943:-BLCAMetforminEER3.2350e-020.1619image
chr11:119016073-119016943:-BRCAErlotinibEER3.3903e-02-0.1578image
ENSG00000118181.9,RPS25BRCAErlotinibEAG4.3585e-02-0.1502image
ENSG00000118181.9,RPS25CESCAZD6482EAG2.5712e-020.2448image
chr11:119016073-119016943:-CESCAZD6482EER2.7045e-020.2442image
chr11:119016073-119016943:-COADATRAEER2.4233e-03-0.3545image
ENSG00000118181.9,RPS25COADATRAEAG2.4233e-03-0.3545image
ENSG00000118181.9,RPS25DLBCBexaroteneEAG6.0729e-03-0.5142image
ENSG00000118181.9,RPS25ESCAImatinibEAG8.1989e-04-0.3466image
chr11:119016073-119016943:-ESCAImatinibEER8.1989e-04-0.3466image
ENSG00000118181.9,RPS25GBMJNK.Inhibitor.VIIIEAG3.4532e-030.4626image
chr11:119016073-119016943:-GBMJNK.Inhibitor.VIIIEER3.4532e-030.4626image
ENSG00000118181.9,RPS25HNSCKU.55933EAG1.4328e-020.3478image
chr11:119016073-119016943:-HNSCKU.55933EER1.4328e-020.3478image
chr11:119016073-119016943:-KIRCAMG.706EER2.0914e-02-0.2473image
ENSG00000118181.9,RPS25KIRCAMG.706EAG2.0914e-02-0.2473image
ENSG00000118181.9,RPS25KIRPAZD6244EAG2.0101e-02-0.3455image
chr11:119016073-119016943:-KIRPAZD6244EER2.0101e-02-0.3455image
ENSG00000118181.9,RPS25LGGCGP.082996EAG5.3005e-03-0.2999image
chr11:119016073-119016943:-LGGCGP.082996EER5.3005e-03-0.2999image
ENSG00000118181.9,RPS25LIHCCGP.082996EAG3.2452e-020.3850image
chr11:119016073-119016943:-LIHCCGP.082996EER3.2452e-020.3850image
chr11:119016073-119016943:-LUADKU.55933EER2.5595e-020.1632image
ENSG00000118181.9,RPS25LUADKU.55933EAG2.5595e-020.1632image
ENSG00000118181.9,RPS25LUSCA.443654EAG8.4576e-03-0.1784image
chr11:119016073-119016943:-LUSCA.443654EER8.4576e-03-0.1784image
chr11:119016073-119016943:-OVLenalidomideEER1.1177e-020.1877image
ENSG00000118181.9,RPS25OVAICAREAG1.0334e-020.1897image
ENSG00000118181.9,RPS25PAADGefitinibEAG7.4900e-030.3668image
chr11:119016073-119016943:-PAADGefitinibEER7.4900e-030.3668image
ENSG00000118181.9,RPS25PCPGGefitinibEAG1.0697e-020.4919image
chr11:119016073-119016943:-PCPGGefitinibEER1.0697e-020.4919image
chr11:119016073-119016943:-PRADFH535EER2.7274e-020.1735image
ENSG00000118181.9,RPS25PRADFH535EAG2.7274e-020.1735image
chr11:119016073-119016943:-READMG.132EER8.7476e-03-0.5034image
ENSG00000118181.9,RPS25READMG.132EAG8.7476e-03-0.5034image
ENSG00000118181.9,RPS25SKCMImatinibEAG1.7284e-02-0.2967image
chr11:119016073-119016943:-SKCMImatinibEER1.7284e-02-0.2967image
chr11:119016073-119016943:-STADLenalidomideEER1.0247e-020.2472image
ENSG00000118181.9,RPS25STADLenalidomideEAG1.0247e-020.2472image
ENSG00000118181.9,RPS25THCACGP.082996EAG4.2982e-02-0.2008image
chr11:119016073-119016943:-THCACGP.082996EER4.2982e-02-0.2008image
ENSG00000118181.9,RPS25THYMCCT018159EAG4.1299e-020.2761image
chr11:119016073-119016943:-UCECDMOGEER3.6524e-020.2233image
chr11:119016073-119016943:-UCSJNJ.26854165EER2.2045e-02-0.3915image
ENSG00000118181.9,RPS25UCSJNJ.26854165EAG2.2045e-02-0.3915image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType